These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23292238)

  • 1. Surviving the cure: long term followup of hematopoietic cell transplant recipients.
    Majhail NS; Rizzo JD
    Bone Marrow Transplant; 2013 Sep; 48(9):1145-51. PubMed ID: 23292238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
    Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.
    Rizzo JD; Wingard JR; Tichelli A; Lee SJ; Van Lint MT; Burns LJ; Davies SM; Ferrara JL; Socié G
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):138-51. PubMed ID: 16443512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
    Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
    Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term complications after hematopoietic cell transplantation.
    Majhail NS
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):220-227. PubMed ID: 28641097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant serum FT3 levels in recipients predict early non-relapse mortality after myeloablative allogeneic haematopoietic cell transplantation from matched sibling donors.
    Li H; Chen J; Shi B; Chen X; Wu D; Wang Y
    Hematology; 2018 Jan; 23(1):38-43. PubMed ID: 28651453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.
    Majhail NS; Rizzo JD; Lee SJ; Aljurf M; Atsuta Y; Bonfim C; Burns LJ; Chaudhri N; Davies S; Okamoto S; Seber A; Socie G; Szer J; Van Lint MT; Wingard JR; Tichelli A; ; ; ; ; ; ;
    Bone Marrow Transplant; 2012 Mar; 47(3):337-41. PubMed ID: 22395764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation.
    Cheon J; Lee YJ; Jo JC; Kweon K; Koh S; Min YJ; Park SH; Lee SH; Kim HJ; Choi Y
    Support Care Cancer; 2021 Feb; 29(2):975-986. PubMed ID: 32556712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT).
    Rizzo JD; Wingard JR; Tichelli A; Lee SJ; Van Lint MT; Burns LJ; Davies SM; Ferrara JL; Socié G
    Bone Marrow Transplant; 2006 Feb; 37(3):249-61. PubMed ID: 16435004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hematopoietic cell transplant survivors in the United States.
    Majhail NS; Tao L; Bredeson C; Davies S; Dehn J; Gajewski JL; Hahn T; Jakubowski A; Joffe S; Lazarus HM; Parsons SK; Robien K; Lee SJ; Kuntz KM
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1498-501. PubMed ID: 23906634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
    Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care utilization by adult long-term survivors of hematopoietic cell transplant: report from the Bone Marrow Transplant Survivor Study.
    Shankar SM; Carter A; Sun CL; Francisco L; Baker KS; Gurney JG; Weisdorf DG; Forman SJ; Robison LL; Grant M; Bhatia S
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):834-9. PubMed ID: 17416780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.
    Majhail NS; Rizzo JD; Lee SJ; Aljurf M; Atsuta Y; Bonfim C; Burns LJ; Chaudhri N; Davies S; Okamoto S; Seber A; Socie G; Szer J; Van Lint MT; Wingard JR; Tichelli A; ; ; ; ; ; ;
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):348-71. PubMed ID: 22178693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation.
    Baker KS; Chow E; Steinberger J
    Bone Marrow Transplant; 2012 May; 47(5):619-25. PubMed ID: 21643022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late effects after hematopoietic stem cell transplantation--critical issues.
    Tichelli A; Rovó A; Socié G
    Curr Probl Dermatol; 2012; 43():132-49. PubMed ID: 22377926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-endocrine late complications in children after allogeneic haematopoietic SCT.
    Faraci M; Békássy AN; De Fazio V; Tichelli A; Dini G;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S49-57. PubMed ID: 18545245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
    Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.